

PCTWORLD INTELLECTUAL PROI
International I

INTERNATIONAL APPLICATION PUBLISHED UNDE

WO 9607444A1

(51) International Patent Classification⁶ :

A61M 5/32, B05D 3/00, 1/18

A1

(11) Internati nal Publication Number:

WO 96/07444

(43) Internati nal Publicati n Date:

14 March 1996 (14.03.96)

(21) International Application Number: PCT/US95/11385

(22) International Filing Date: 6 September 1995 (06.09.95)

(30) Priority Data:

303,866

9 September 1994 (09.09.94)

US

(71) Applicant: BIOSEAL, LIMITED LIABILITY CORPORA-
TION [US/US]; 7126 West Garfield Avenue, Wauwatosa,
WI 53212 (US).(72) Inventors: NIKOLAYCHIK, Victor; 112F East Freistadt,
Mequon, WI 53092 (US). KIPSHIDZE, Nicholas, N.;
Apartment 212, 9009 North White Oak Lane, Bayside, WI
53217 (US). BAKER, John, E.; 7126 West Garfield Avenue,
Wauwatosa, WI 53212 (US).(74) Agents: SWARTZ, Douglas, W. et al.; Sheridan Ross &
McIntosh, Suite 3500, 1700 Lincoln Street, Denver, CO
80203 (US).(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH,
CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE,
KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
TJ, TM, TT, UA, UZ, VN, European patent (AT, BE, CH,
DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE),
OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,
NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).


Published

With international search report.

(54) Title: METHOD OF MAKING FIBRIN COATED SUBSTRATES

(57) Abstract

A method is provided for forming fibrin coatings (30) on a substrate, such as device (64) for implantation in a body. The fibrin coatings (30) are dried (48) to provide a fibrin coating (52) having the ability to be stored (56) for extended periods before use. To provide coatings (30) having high shear force resistance, the substrate is contacted first with thrombin (26) and second with fibrinogen (226).



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo			SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
CI	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

METHOD OF MAKING FIBRIN COATED SUBSTRATES

FIELD OF THE INVENTION

This invention relates generally to fibrin-coated
5 devices for implantation in a body and specifically to
fibrin-coated stents.

BACKGROUND OF THE INVENTION

Partial or complete blockage of blood vessels is
10 rapidly becoming a major cause of injury or death. Blood
vessel blockages can result in a variety of physical
ailments including heart attacks and strokes. Blood vessel
blockages may be caused by a variety of agents, including
blood clots and the build up of cholesterol on a blood
15 vessel.

Blood vessel blockage is typically treated by
bypassing the blocked portion of the blood vessel. The
bypass is generally accomplished by using either a graft
from a patient's blood vessel or a synthetic conduit.

20 Alternatively, the blocked portion of the vessel may
be reopened or replaced by a vascular stent composed of
metal or synthetic materials. In some cases, stents are
preferred instead of grafts, because, unlike grafts, stents
can be implanted without a surgical procedure. Further,
25 the risks of restenosis (e.g., a narrowing of a blood
passageway) is decreased with stents relative to grafts.

The use of stents to reopen or replace the blocked
portion of the blood vessel can create complications.
Stents can themselves induce partial or complete blocking

-2-

of the blood vessel by triggering blood clotting in the vicinity of the stent. After implantation, the natural process of fibrin deposition on the stent occurs to initiate the healing process. The deposition of the fibrin in the presence of thrombin triggers platelet activation and the formation of a thrombus or embolus. Bound thrombin can also induce the formation of more fibrin on the stent, thereby narrowing the luminal area of the stent. The reduced luminal area can cause an embolism in the patient.

Several approaches have been employed to overcome the complications associated with vascular stents. In one approach, an anticoagulant is administered to the patient to reduce the likelihood of clotting. Anticoagulants are not widely used because they can cause serious injury or death. In another approach, endothelial cells, the cells lining blood and lymphatic vessels, are seeded onto the stent to facilitate the healing process. The seeding of stents with endothelial cells is also not widely used because seeded stents are difficult, if not impossible, to manufacture. In yet another approach, a fibrin coating is deposited on the stent before implantation to facilitate the healing process. Compared to stents implanted without a fibrin coating, the incorporation of a fibrin coating on an implanted stent reduces significantly the likelihood of blood vessel blockage after implantation.

The approach of forming a fibrin coating on a stent before implantation to reduce or overcome complications has several drawbacks which significantly increase the cost of

-3-

the fibrin-coated stent. For example, a fibrin coating is unstable outside of the body and generally must be implanted immediately after formation of the coating. A fibrin coating generally does not adhere tightly to the stent and can become dislodged easily from the stent surface. A denatured fibrin coating has been used to enhance adhesion of the coating to the stent surface, but denatured fibrin has a different structure than natural fibrin (e.g., fibrin formed in the body) leading to an increased risk of blood clots. Consequently, denatured fibrin is not as effective as a natural fibrin coating in enhancing healing and reducing the likelihood of blood clotting after implantation.

Accordingly, there is a need for a device to be implanted in a body, such as a stent, having a low risk of inducing blood clot formation after implantation of the device in a body.

There is a further need for an improved method for seeding a device to be implanted in a body with endothelial cells.

There is a further need for a device to be implanted in a body having a fibrin coating that is stable outside the body. There is a related need for a device to be implanted in a body having a fibrin coating that may be stored for long periods before use.

There is a further need for a fibrin coating that has a high degree of adhesion to the surface of the device. There is a related need for a fibrin coating containing a

-4-

substantial amount of naturred fibrin and a limit d amount of denatured fibrin.

SUMMARY OF THE INVENTION

5 One embodiment of the present invention provides a method for forming a fibrin coating on a substrate, particularly on a device for implantation in a body. Th method includes the following steps: (i) contacting the substrate with thrombin and fibrinogen to form the fibrin
10 coating on a portion of the substrate and (ii) drying the fibrin coating at a temperature and pressure and for a time sufficient to vaporize a substantial portion of the water in the fibrin coating and thereby cause the coating to adhere to the substrate.

15 In the contacting step, the substrate can be contacted with thrombin and fibrinogen either separately or together. In the former case, the substrate is preferably contacted with thrombin in the substantial absence of fibrinogen to form a thrombin coating on the substrate and the thrombin-
20 coated substrate is contacted with fibrinogen to form the fibrin coating. In the latter case, the substrate is preferably contacted with a liquid containing both thrombin and fibrinogen.

 During contacting, the substrate is preferably
25 contacted with fibrinogen at a temperature of no more than about 56°C to avoid denaturing of the fibrinogen. More pr ferably, the substrate is contacted with fibrinog n at a temperature ranging from about 37 to about 56°C.

-5-

To provide acceptable rates of fibrin formation, the contacting step is preferably conducted in an atmosphere having a humidity of no less than about 90%.

During the drying step, the temperature and time are preferably selected to cause the removal of water from the fibrin coating. Preferably, the temperature ranges from about 37 to about 65°C and the time from about 2 to about 24 hrs. After drying, the thickness of the fibrin coating is less than the thickness of the fibrin coating before drying.

After drying, the fibrin coating can be contacted with water, salts and/or a suitable additive for implantation of the substrate into a living body. After contacting the coating with water, salts and/or a suitable additive and before implantation, the fibrin coating can be seeded with living cells to reduce the thrombogenicity of the coating.

Another embodiment of the present invention provides a device for implantation in a living body. The device includes a structural member, such as a prosthetic device, having a fibrin coating on a surface of the member. As used herein, "prosthetic device" shall refer to a substitute for a diseased or missing body part. The water content of the fibrin coating is reduced to no more than about 8% by weight water to increase the useful life of the device before implantation.

The coating can include various additives. The additives include a substance selected from a group consisting of blood clotting inhibitors, anti-inflammatory

-6-

drugs, smooth muscle cell growth inhibitors, endothelial cell stimulators, antineoplastic reagents, antibiotics, genetic material, and mixtures thereof. As used herein, "anti-inflammatory drug" refers to a substance that reduces inflammation by acting on body mechanisms, without directly antagonizing the causative agent. "Stimulator of endothelial cell growth" refers to a protein that stimulates the growth and/or attachment of endothelial cells and/or chemotaxis. "Antineoplastic reagent" refers to any substance preventing the development, maturation, or spread of neoplastic cells. "Antibiotic" refers to a soluble substance derived either naturally from a mold or bacteria or synthetically that inhibits the growth of microorganisms.

The coating preferably has certain properties. No more than about 19% by weight of the fibrin in the coating should be denatured. The coating should have a thrombogenicity of no more than about 115% of the thrombogenicity of a normal blood vessel wall. The thrombogenicity measures the ability of the coating to trigger clotting of blood contacting the coating. The coating should have a thickness ranging from about 10 to about 200 microns.

Yet another embodiment of the present invention provides another method for forming a fibrin coating on a substrate. The method includes the following steps: (i) contacting the substrate with thrombin in the substantial absence of fibrinogen and (ii) contacting the substrate

-7-

with fibrinogen to form a fibrin coating on a portion of the substrate. The method can further include a drying step at a temperature and pressure and for a time sufficient to vaporize a substantial portion of the water
5 in the fibrin coating.

The present invention has several advantages over existing substrates to be implanted in a living body. The incorporation of a fibrin coating on substrates of the present invention creates a low risk of blood clot
10 formation after implantation of the substrate. The fibrin coatings of the present invention further provide a suitable environment for seeding the substrate with endothelial cells to reduce the thrombogenicity of the substrate. Fibrin coatings of the present invention can be
15 stable outside the body and stored for extended periods before use. Fibrin coatings of the present invention can be deposited on an unpolished substrate which forms stronger coatings than coatings deposited on a polished substrate. The irregular topography of the unpolished
20 substrate allows a greater contact area for fibrin attachment and limits movement of the fibrin coating. Fibrin coatings of the present invention can be sterilized without complete protein denaturation because drying temperatures are typically below the denaturing
25 temperature. The drying step beneficially kills many viruses not killed by fibrin deposition processes which have no drying step. Fibrin coatings of the present invention can have a high degree of adhesion to the

-8-

substrate surface and high shear stress resistivity to blood flow. This advantage is especially useful to resist the high shear forces encountered in intravascular applications. Finally, the fibrin coatings of the present invention can contain a substantial amount of naturesd fibrin and a limited amount of denatured fibrin. The presence of naturesd fibrin in the coating reduces the thrombogenicity of the coating.

10

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a flow chart of a process according to the present invention; and

Fig. 2 is a side view of an incubation chamber.

15

DETAILED DESCRIPTION

The present invention provides a method for coating a surface of a substrate with fibrin. An important aspect of the invention is the use of a drying step after formation of the fibrin coating to remove water from the coating.

20 The drying step causes the coating to adhere to the substrate and provides a coating that may be stored for extended periods before use. Another important aspect of the invention is the application of thrombin to the substrate followed by contact of the thrombin with

25 fibrinogen to form fibrin. This process produces fibrin coatings having a high degree of adhesion to the substrate surface.

-9-

The substrate can be composed of any material that is safe for use in a living body. Preferably, the substrate is composed of a polymeric material, such as poly(ethylene terephthalate), polyethylene, polyurethane, poly(lactic acid), poly(glycolic acid), or poly(tetrafluoroethylene); a metal, such as stainless steel titanium, nitinol, and other alloys; or composites of a polymeric material and a metal. The substrate is preferably a prosthetic device, such as a stent, an artificial heart valve, a cardiac-assist device, or the surfaces of an artificial heart. The substrate can also be a nonprosthetic device, such as a breast implant, pacemaker, or the wires to a pacemaker.

The substrate is contacted with thrombin and fibrinogen to form a fibrin coating on a portion of the substrate. While not wishing to be bound by any theory, it is believed that the fibrin is formed by the action of the thrombin on the fibrinogen. It is believed that the thrombin hydrolyzes peptide bonds in the fibrinogen, which converts fibrinogen to fibrin monomers. The fibrin monomers polymerize to form long-chain polymers which interlock to form a jelly-like mass.

To form the fibrin coating on the substrate, the substrate is preferably contacted first with thrombin in the substantial absence of fibrinogen and second with fibrinogen in the substantial absence of thrombin. As noted above, it has been discovered that contacting the substrate with thrombin before fibrinogen results in a fibrin coating that strongly adheres to the substrate

-10-

surface. While not wishing to be bound by any theory, it is believed that the presence of thrombin on the substrate surface causes the fibrinogen to form fibrin immediately upon contact with the surface. The direct formation of
5 fibrin on the surface is believed to cause the fibrin monomers to attach directly to the surface.

The thrombin and fibrinogen are preferably contacted with the substrate as separate liquids. A first liquid contains the thrombin, and a second liquid contains the
10 fibrinogen. The first and second liquids are preferably aqueous solutions having a pH ranging from about 6.8 to about 7.8.

The concentrations of the thrombin and fibrinogen in the first and second liquids determine the thickness of the
15 fibrin coating. In the first liquid, the concentration of the thrombin should range from about 0.001 to about 1000 IU/ml, more preferably from about 0.05 to about 500 IU/ml, and most preferably from about 0.1 to about 100 IU/ml. The first liquid is substantially free of fibrinogen,
20 preferably having a concentration of fibrinogen that is no more than about 15 ng/ml. In the second liquid, the concentration of the fibrinogen should range from about 5 to about 75 mg/ml, more preferably from about 5 to about 50 mg/ml, and most preferably from about 10 to about 30 mg/ml.
25 The second liquid is preferably substantially free of thrombin, preferably having a concentration of thrombin that is no more than about 0.0001 IU/ml.

-11-

The first and second liquids can contain a stabilizing salt to solubilize the thrombin and/or fibrinogen in the liquids. The stabilizing salt can be any salt, including sodium chloride, magnesium sulfate, sodium sulfate, potassium chloride, calcium chloride, and mixtures thereof. Preferably, the salt concentration in the solution ranges from about 50 to about 300 mOsmoles/liter.

The second liquid can contain other additives to impact the properties of the fibrin coating and the reaction of the body to the coating after implantation. The additive can be contacted with the second liquid either as is or as a part of a time-release microcapsule. The time-release microcapsule is typically used where the additive is a medication that is to be released gradually into the body over time.

One additive is a stabilizing agent to stabilize the fibrin coating. While not wishing to be bound by any theory, it is believed that the stabilizing agent catalyzes cross-linking of the fibrin polymers. The cross-linking stabilizes the deposited fibrin, making it resistant to the high fluid shear rates to which intravascular prosthetic devices, such as stents, are subjected. Stabilizing agents include Factor XIII, calcium salts that are soluble in the second liquid (e.g., calcium chloride), and derivatives and mixtures thereof. Preferably, the Factor XIII has a concentration in the second liquid ranging from about 5 to about 500 IU/ml, and the calcium salt a concentration ranging from about 0.1 to about 15 mg/dl.

-12-

Another additive is a blood clotting inhibitor (e.g., anti-coagulant) to inhibit the formation of blood clots after implantation of the substrate. Preferred blood clotting inhibitors include recombinant hirudin, hirulog-1, D-phenylalanyl-L-prolyl-L-arginyl chloromethyl keton, heparin and its fractions, dipyridamole, RGD-like peptide, and derivatives and mixtures thereof. The blood clotting inhibitors are generally used at pharmacological concentrations to prevent clotting. The blood clotting inhibitor heparin preferably has a concentration in the second liquid ranging from about 10 to about 500 IU/ml, preferably about 50 to about 250 IU/ml, and more preferably from about 75 to about 150 IU/ml. Dipyridamole preferably has a concentration ranging from about 10 to about 100 moles/ml.

Yet another additive is an anti-inflammatory drug to suppress inflammation of tissue after implantation of the substrate. Anti-inflammatory drugs preferably include antihistamines, glucocorticoids, non-steroidals, salicylates, steroids, and derivatives and mixtures thereof. The anti-inflammatory drug is generally used in the second liquid at pharmacological concentrations.

Yet another additive is an inhibitor of smooth muscle cell growth. In intravascular applications, smooth muscle cells in the blood vessel wall can grow into the blood vessel. The constriction of the luminal area of the blood vessel can cause partial or complete blockage of the blood vessel. Inhibitors of smooth muscle cell growth retard the

-13-

formation of such constrictions. Preferred inhibitors include nitric oxide donors such as nitrosoglutathione, substrates for nitric oxide production such as L-arginine, and derivatives and mixtures thereof. The inhibitor is
5 generally used in the second liquid at pharmacological concentrations. Specifically, the concentration of L-arginine ranges from about 0.1 to about 5.0 μM and nitrosoglutathione from about 0.1 to about 50 μM .

Yet another additive is a stimulator of endothelial
10 cell growth. In intravascular applications, endothelial cells coat the interior of the blood vessel to separate the blood from the underlying smooth muscles of the blood vessel wall. The contact of the blood with the smooth muscles can cause rapid reproduction of the smooth muscle
15 cells and constriction of the luminal area of the vessel. Preferred stimulators of endothelial cell growth include basic fibroblast cell growth factor, endothelial cell growth factor, α_2 macroglobulin, vitronectin, fibronectin, fibronectin fragments containing binding determinants for
20 endothelial cells, and derivatives and mixtures thereof. The stimulator is generally used at pharmacological concentrations. Specifically, fibronectin preferably has a concentration in the second liquid ranging from about 5 to about 150 ng/ml.

25 Yet another additive is an antineoplastic reagent. Antineoplastic reagents are particularly useful for substrates contacting a cancerous cell growth to inhibit cell proliferation in the growth. Preferred antineoplastic

-14-

reagents include doxorubicin, taxol, methotrexate, and derivatives and mixtures thereof. The antineoplastic reagent is generally used at pharmacological concentrations. Specifically, doxorubicin preferably has
5 a concentration in the second liquid ranging from about 0.1 to about 1.0 mg/ml.

Yet another additive is an antibiotic. Antibiotics are used to prevent infection after implantation of the substrate. Preferred antibiotics include all broad and
10 medium spectrum agents, including aminoglycosides, cephalosporons (1st, 2nd, and 3rd generation), macrolids, penicillins, tetracyclines, and derivatives and mixtures thereof. The antibiotic is generally used at pharmacological concentrations. Specifically, tobramycin
15 preferably has a concentration in the second liquid ranging from about 10 to about 50 mg/ml.

As will be appreciated, other additives can be incorporated in the second liquid depending upon the desired properties of the coating or the desired effect of
20 the coating on the patient. For example, genetic material may be incorporated with endothelial cells in the second liquid to assist in nitric oxide production by the substrate.

To form the fibrin coating, the substrate can be
25 immersed sequentially in the first and second liquids. Immersing the substrate in the first liquid forms a liquid coating of thrombin on the substrate. The thrombin coating

-15-

forms fibrin when the substrate is contacted with the second liquid containing fibrinogen.

During immersion of the substrate in the first liquid, the temperature of the liquid preferably ranges from about 21 to about 37°C, and the time of immersion preferably ranges from about 2 to about 24 hrs.

During immersion of the substrate in the second liquid, the temperature of the liquid is preferably maintained below the temperature at which denaturing of the fibrinogen occurs. In human fibrinogen, denaturing typically occurs at temperatures of 56°C or more. As noted above, denatured fibrinogen forms a fibrin coating having a higher thrombogenicity than a fibrin coating formed from natured fibrin. Preferably, the temperature ranges from about 37 to about 56°C.

It is most preferred that the temperature of the second liquid be maintained as closely as possible at the temperature of the body in which the substrate is to be implanted (e.g., 37°C for humans) to reproduce as closely as possible the conditions of fibrin formation in the body. Such a temperature favors the formation of a fibrin coating having properties that closely resemble those of a fibrin coating formed in the body.

The time of immersion of the substrate in the second liquid determines the thickness of the fibrin coating. Preferably, the thickness of the fibrin coating after immersion ranges from about 400 to about 5,000 microns. To

-16-

obtain this thickness, the time of immersion preferably ranges from about 4 to about 20 hrs.

The humidity of the ambient atmosphere is another important factor to fibrin formation. It has been discovered that the humidity of the atmosphere contacting the surface of the second liquid is directly related to the rate of conversion of fibrinogen into fibrin. Preferably, the humidity of the atmosphere is no less than about 90%, more preferably no less than about 92%, and most preferably no less than about 96%.

There are other methods to contact the substrate with thrombin and fibrinogen. Thrombin and fibrinogen also can be contacted with the substrate by spraying the first and/or second liquids on the substrate. As will be appreciated, the thrombin and fibrinogen can also be contacted with the substrate by a combination of immersion and spraying of the first and/or second liquids. Immersion of the substrate in both of the first and second liquids is preferred because this creates greater surface contact area, greater coating flexibility, and a more uniform coating.

Alternatively, the fibrin coating can be formed by contacting the substrate with a single liquid containing both thrombin and fibrinogen. This approach has the advantage of using only one liquid, rather than two liquids, in the formation of the fibrin coating; however, the use of two liquids as described above is believed to form a fibrin coating that adheres to the substrate more

-17-

strongly than a fibrin coating formed from a single liquid containing both thrombin and fibrinogen.

As yet another alternative, the thrombin and fibrinogen can be applied to the substrate as a solid rather than as a liquid. However for purposes of simplicity and cost, it is preferred to apply thrombin and fibrinogen to the substrate as a liquid.

After formation of the fibrin coating, the coating can be dried at a temperature and pressure and for a time sufficient to vaporize a substantial portion of the water in the fibrin coating and thereby cause the coating to adhere to the substrate. After formation, the fibrin coating has a water content ranging from about 80 to about 96% by weight. As noted above, it is believed that removal of water from the fibrin coating has several advantages, including the ability to store the fibrin coating for extended periods before use and increased adhesion of the coating to the substrate surface. While not wishing to be bound by any theory, it is believed that water acts as a lubricant between the fibrin coating and the substrate and that the water increases the thickness of the coating and decreases the ability of the fibrin polymers to contact one another. In each case, the net result is a decrease in the adhesive forces between the coating and the substrate and the shear strength of the coating. Removal of the water increases the adhesive forces and the shear strength of the coating.

-18-

The temperature of the coating during drying is below the melting point of the substrate. Preferably, the coating temperature ranges from about 37 to about 65°C, more preferably from about 45 to about 52°C, and most preferably from about 50°C to about 51°C.

The pressure during drying is preferably maintained at about atmospheric pressure. The use of higher or lower pressures can significantly increase the cost of the drying equipment.

The time of drying is selected to remove a substantial portion of the water from the coating while suppressing denaturing of the fibrin for drying temperatures in excess of the temperature at which denaturing occurs. Preferably, the time is selected such that drying reduces the water content of the coating to no more than about 8% by weight, more preferably no more than about 5% by weight, and most preferably no more than about 3% by weight. Preferably, the time is also selected such that no more than about 19% by weight, more preferably no more than about 15% by weight, and most preferably no more than about 13% by weight of the fibrin in the fibrin coating is denatured after drying. Accordingly, the time ranges from about 2 to about 24 hrs, more preferably from about 4 to about 20 hrs, and most preferably from about 6 to about 18 hrs.

The composition of the ambient atmosphere during drying is an important aspect of the drying step. The atmosphere should be sterile and have less than a saturation amount of water vapor to facilitate water

-19-

removal from the coating. Preferably, the atmosphere is substantially composed of an inert gas, such as nitrogen or argon.

After drying, the thickness of the fibrin coating is reduced and the density of the coating increased. Typically, the thickness of the fibrin coating after drying is no more than about 5% of the thickness of the coating before drying. As a consequence, the thickness of the coating after drying preferably ranges from about 10 to about 200 microns.

After drying, the fibrin coating has a low thrombogenicity compared to conventional fibrin coatings. Preferably, the thrombogenicity of the coating is no more than about 115% of the thrombogenicity of a normal blood vessel wall.

Before implantation of the dried fibrin coating in a body, it is important to add water, salt, and pharmacologic agents to the fibrin coating. Before use, the dried fibrin coating is preferably contacted with water and salts to increase the flexibility and non-thrombogenicity of the coating to acceptable levels for implantation. The moisture content of the dried fibrin coating is preferably increased by immersing the coating in water or exposing the coating to water vapor. Surprisingly, the thickness of the coating after rehydration is less than the coating thickness before drying. Relative to stents, the reduced thickness provides an increased luminal area of a stent.

-20-

Following the replenishment of water to the coating, the fibrin coating can be seeded with endothelial cells to further reduce the thrombogenicity of the coating. The stability of the fibrin coating makes it an excellent substrate for endothelial cell seeding. Endothelial cells can be obtained by standard procedures from umbilical vein, saphenous vein, microvessels of fat-containing tissues, or other sources. For seeding, the cells are cultured on the coating in the presence of a culture medium, generally at body temperature in an atmosphere containing carbon dioxide. Satisfactory attachment of the endothelial cells to the fibrin coating is generally realized within about 1 and about 3.5 hrs. After seeding, the fibrin coating is incubated to allow the endothelial cells to reproduce.

Alternatively when the coating is not to be dried before implantation, cultured endothelial cells can be included within the second liquid to trap the cells within the coating. The coating is then incubated as noted above. Drying the coating will kill the endothelial cells.

Smooth muscle cells, fibroblasts and/or derivatives and/or mixtures thereof with endothelial cells may also be included in the second liquid and the fibrin coating.

Referring to Fig. 1, the preferred embodiment of the present invention, the substrate 10 is prepared before formation of the fibrin coating to form a clean substrate 18. Typically, the substrate is cleaned and sterilized by being rinsed with methanol or ethanol to remove contaminants. The methanol or ethanol rinse is

-21-

followed by a rinse in tris buffered solution ("TBS") or phosphate buffered solution ("PBS"). As necessary, the clean substrate 18 can be stored in TBS or PBS.

The clean substrate 18 is contacted 22 a, b with
5 thrombin and fibrinogen to form the fibrin coating. The clean substrate 18 is immersed in a first liquid containing thrombin to form a thrombin-coated substrate 26. The thrombin-coated substrate 26 is immersed in a second liquid containing fibrinogen and one or more of the additives 28
10 noted above to deposit the fibrinogen on the thrombin-coated substrate 26 and form a fibrin-coated substrate 30.

The size and design of the vessel used for fibrin formation depends on the size and shape of clean substrate 18. The preferred vessel design for a stent is
15 depicted in Fig. 2. The vessel 34 includes a cylindrical member 38 that has a size that closely matches the inner diameter of the stent 42. The vessel interior 44 is filled sequentially with the first and second liquids to form the fibrin coating on the stent 42. The vessel 34 can include
20 heating elements (not shown) to maintain the temperature of the first and second liquids at desired levels.

The fibrin-coated substrate is dried 48 to remove water from the fibrin to yield a dried fibrin-coated substrate 52.

25 Known dryers can be utilized to dry the fibrin coating. The size and shape of the dryer depends upon the size, shape and composition of the substrate.

-22-

The dried fibrin-coated substrate 52 is stored 56 under sterile conditions for an extended period and wetted 60 with water, salts and/or the additives noted above for implantation in the patient 64.

5

EXAMPLES

A series of experiments were conducted to evaluate the effects of drying on the properties of fibrin coatings. During the experiments, the following reagents were used:

10	Fibrinogen	10-30 mg/ml
	Thrombin	0.1-100 IU/ml
	Heparin	10-500 IU/ml
	Dipyridamole	10-100 moles/ml
	RGD-Like Peptide	0.1-100 ng/ml

15 The fibrinogen, thrombin, and other reagents were combined in an aqueous solution in the presence of a stent at room temperature. The solution was not agitated.

After 2-10 minutes, the stent was transferred to an incubator at 37°C and 90% humidity for 10-12 hours.

20 Thereafter, factor XIII was contacted with the solution at 37°C for approximately 2 hours.

The stent was transferred to an oven for 6-18 hours for drying.

25 The concentrations of the fibrinogen and thrombin and oven temperatures during the various experiments are set forth below:

-23-

	<u>Reagent</u>		<u>Drying Oven Temperature</u>
1.	Fibrinogen	10 mg/ml	45°C
	Thrombin	5 IU/ml	
2.	Fibrinogen	30 mg/ml	45°C
5	Thrombin	5 mg/ml	
3.	Fibrinogen	10 mg/ml	56°C
	Thrombin	5 IU/ml	
4.	Fibrinogen	30 mg/ml	56°C
	Thrombin	5 IU/ml	

10

After formation, the fibrin coatings were examined under intense light and electron microscopy. The coatings were found to be uniform and substantially free of cracking.

15 The fibrin-coated stents were then mounted on a balloon and the balloon expanded to replicate the mounting of the stent on a blood vessel. The stent was again examined under intense light and electron microscopy. The fibrin coating was still found to be uniform and
20 substantially free of cracks.

The foregoing description of the invention has been presented for purposes of illustration and description. Further, the description is not intended to limit the invention to the form discussed herein. Consequently,
25 variations and modifications commensurate with the above teachings, and the skill or knowledge in the relevant art are within the scope of the present invention. The preferred embodiment described hereinabove is further

-24-

intend d to explain the best mode of practicing the
inv ntion and to enable others skilled in the art to
utilize the invention in various embodiments and with th
various modifications required by their particular
5 applications or uses of the invention. It is intended that
the appended claims be construed to include alternate
embodiments to the extent permitted by the prior art.

-25-

What is claimed is:

1. A method for forming a fibrin coating on a substrate, comprising the steps of:

(a) providing the substrate;

5 (b) contacting the substrate with thrombin and fibrinogen to form a fibrin coating on a portion of the substrate, wherein the fibrin coating comprises water; and

(c) drying the fibrin coating at a temperature and pressure and for a time sufficient to vaporize a
10 substantial portion of the water in the fibrin coating and thereby cause the coating to adhere to the substrate.

2. The method, as claimed in Claim 1, wherein:
the substrate is a device for implantation in a body.

3. The method, as claimed in Claim 1, wherein said
15 contacting step comprises:

first contacting the substrate with thrombin in the substantial absence of fibrinogen to form a thrombin coating on a portion of the substrate; and

second contacting the substrate with fibrinogen to
20 form the fibrin coating.

4. The method, as claimed in Claim 1, wherein the contacting step comprises:

contacting the substrate with a liquid comprising thrombin and fibrinogen.

25 5. The method, as claimed in Claim 1, wherein:
in said contacting step, the substrate is contacted with a liquid comprising from about 0.001 to about 1000 IU/ml of thrombin.

-26-

6. The method, as claimed in Claim 1, wherein:
in th contacting step, the substrate is contact d
with a liquid comprising from about 5 to about 75 mg/ml
fibrinogen.

5 7. The method, as claimed in Claim 1, wherein:
the contacting step is conducted at a temperature
below the temperature at which the fibrinogen becomes
denatured.

8. The method, as claimed in Claim 1, wherein:
10 in the contacting step, the substrate is contacted
with fibrinogen at a temperature ranging from about 37 to
about 56°C for a time sufficient to induce formation of the
fibrin coating.

9. The method, as claimed in Claim 1, wherein:
15 in the contacting step, the substrate is contacted
with a liquid comprising a substance selected from th
group consisting of thrombin, fibrinogen, or mixtures
thereof; and wherein the contacting step comprises:
spraying the liquid onto the substrate to form the
20 fibrin coating.

10. The method, as claimed in Claim 1, wherein:
the contacting step is conducted in an atmospher
having a humidity of no less than about 90%.

11. The method, as claimed in Claim 1, wherein the
25 contacting step comprises:

contacting the fibrin coating with a compound selected
from the group consisting of Factor XIII, a calcium salt,

-27-

and mixtures thereof to catalyze cross-linking of the fibrin.

12. The method, as claimed in Claim 1, wherein:

in the contacting step, the substrate is contacted
5 with a liquid comprising from about 10 to about 500 IU/ml heparin.

13. The method, as claimed in Claim 1, wherein:

in the contacting step, the substrate is contacted
with a liquid comprising from about 10 to about 100
10 moles/ml dipyridamole.

14. The method, as claimed in Claim 1, wherein:

the temperature ranges from about 37 to about 65°C.

15. The method, as claimed in Claim 1, wherein:

the time ranges from about 2 to about 24 hrs.

15 16. The method, as claimed in Claim 1, wherein:

before the drying step, the fibrin coating has a first thickness and after the drying step the fibrin coating has a second thickness, wherein the second thickness is less than the first thickness.

20 17. The method, as claimed in Claim 1, further comprising the steps of:

(d) after the drying step, contacting the fibrin coating with water; and

(e) implanting the substrate into a living body.

25 18. The method, as claimed in Claim 1, further comprising the steps of:

(d) after the drying step, contacting the fibrin coating with water to form a wetted fibrin coating;

-28-

(e) seeding the wetted fibrin coating with living cells; and

(f) implanting the substrate after the seeding step into a living body.

5 19. A substrate having a fibrin coating formed by the process of Claim 1.

20. A device for implantation in a living body, comprising:

10 a structural member having a fibrin coating on a surface of the structural member, wherein the water content of the fibrin coating is reduced to no more than about 8% by weight water to increase the useful life of the device before implantation.

15 21. The device, as claimed in Claim 20, wherein: no more than about 19% by weight of the fibrin in the fibrin coating is denatured.

22. The device, as claimed in Claim 20, wherein the fibrin coating comprises:

20 a substance selected from the group consisting of blood clotting inhibitors, anti-inflammatory drugs, smooth muscle cell growth inhibitors, endothelial cell stimulators, antineoplastic reagents, antibiotics, and mixtures thereof.

25 23. The device, as claimed in Claim 20, wherein: the structural member is a prosthetic device.

-29-

24. The device, as claimed in Claim 20, where in:
the fibrin coating has a thrombogenicity that is no
more than about 115% of the thrombogenicity of a normal
blood vessel wall.

5 25. The device, as claimed in Claim 20, wherein:
the fibrin coating has a thickness ranging from about
10 to about 200 microns.

26. The device, as claimed in Claim 20, wherein:
the fibrin coating includes cells selected from the
10 group consisting of endothelial cells, smooth muscle cells,
fibroblasts, and derivatives and mixtures thereof.

27. A method for forming a fibrin coating on a
substrate, comprising the steps of:

- (a) providing the substrate;
- 15 (b) first contacting the substrate with thrombin in
the substantial absence of fibrinogen; and
- (c) second contacting the substrate with fibrinogen
to form a fibrin coating on a portion of the substrate.

28. The method, as claimed in Claim 27, wherein:
20 the fibrin coating comprises water; and further
comprising the step of:

- (d) drying the fibrin coating at a temperature and
pressure and for a time sufficient to vaporize a
substantial portion of the water in the fibrin coating and
25 thereby cause the coating to adhere to the substrate.




Fig. 1




Fig. 2

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/11385

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61M 5/32; B05D 3/00, 1/18

US CL : 604/265; 427/2.12, 430.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 604/264-266, 890.1-892.1; 427/2.12, 2.24, 2.25, 2.28, 422-424, 430.1; 523/112, 113

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
MERCK CHEMICAL INDEX

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG:

search terms: fibrin, fibronectin, thrombin, coating

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US, A, 5,272,074 (RUBENS) 21 DECEMBER 1993, note columns 1:55-2:6; 3:25-54; 5:50-60.	1,2,5,8,11, 12,14,19 ----- 3,4,6,7,9, 10,13,15- 18,20-28
Y	US, A, 5,298,255 (SAWAMOTO ET AL.) 29 MARCH 1994, see entire reference.	1-28
Y	US, A, 4,453,939 (ZIMMERMAN ET AL.) 12 JUNE 1984, see entire reference.	1-28
Y	US, A, 5,019,393 (ITO ET AL.) 28 MAY 1991, see entire reference.	1-28

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be part of particular relevance	* X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* &*	document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means		
* P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

07 NOVEMBER 1995

Date of mailing of the international search report

21 DEC 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CHALIN SMITH

Telephone No. (703) 308-0858